Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
about
Pharmacology and physiology of gastrointestinal enteroendocrine cellsIntestinal organoids for assessing nutrient transport, sensing and incretin secretionFree fatty acid receptors: structural models and elucidation of ligand binding interactions.GIT2 Acts as a Systems-Level Coordinator of Neurometabolic Activity and Pathophysiological Aging.Homology modeling of FFA2 identifies novel agonists that potentiate insulin secretion.Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4.Investigational insulin secretagogues for type 2 diabetes.Polymorphic Variation in FFA Receptors: Functions and Consequences.Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.Free Fatty Acid Receptors and Cancer: From Nutrition to Pharmacology.Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands.Editorial: Obesity and Diabetes: Energy Regulation by Free Fatty Acid Receptors.Quercetin/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators.Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.Ligands at Free Fatty Acid Receptor 1 (GPR40).IL-1β and TNFα inhibit GPR120 (FFAR4) and stimulate GPR84 (EX33) and GPR41 (FFAR3) fatty acid receptor expression in human adipocytes: implications for the anti-inflammatory action of n-3 fatty acids.Structural basis for GPR40 allosteric agonism and incretin stimulation.Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?
P2860
Q26799380-5E2EA9A2-5588-4F97-A190-45017D3643E7Q27305673-847A73FA-2649-484A-8AB4-CB7EC2FE2A88Q35766268-6C7699B1-8170-4177-9590-087B51CADBA7Q36471894-0636A319-A3EB-474A-9594-26C955005A44Q38645790-0DCD5425-2518-4962-A664-B22936EB4AA7Q38708579-EB8F1E79-7750-4D65-A95A-1B2353A3ECC6Q38735419-329E111E-8B79-4CFD-93C4-A21A37B1C460Q39013784-69BAA22D-F222-40C8-B4CF-97E37F9245D5Q39192856-B7AB75F2-0E30-4E78-AE4A-52CCE90BFC9CQ39273221-F43756F2-EA4A-4AB8-802B-C9C0D72D31BBQ41449385-230B90D3-5858-4412-860B-84B1657EC8D9Q43163798-8B6F2AF1-36FF-4D47-867A-26BA28E80D97Q47611209-81246909-D35C-4FB7-9BF8-D093323E11ABQ51363044-4358B7FD-66C2-4A2A-985C-0858598EB8A5Q51377008-E18C1AB7-926C-4BAF-B19B-7D9D825EC43FQ51823595-31BE39E0-7464-48A1-BD1E-D248E788A002Q52309488-5EAC1B29-FAA1-4460-B739-901AA86BAB85Q57072608-F82FE426-6C21-419A-B44D-23D6B1C91690Q58777105-10A7D8B7-1843-4AB5-83D9-E4C7CE73D2A2
P2860
Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
@en
type
label
Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
@en
prefLabel
Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
@en
P2860
P356
P1476
Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
@en
P2093
Graeme Milligan
Kenneth R Watterson
P2860
P356
10.3389/FENDO.2014.00137
P577
2014-08-28T00:00:00Z